Bio: Dave Anderson serves as Code Bio’s Chief Scientific Officer. He is responsible for guiding the long-term vision for research and discovery and for driving Code Bio’s overall scientific strategy in Duchenne Muscular Dystrophy (DMD), Type 1 Diabetes (T1D), and other serious diseases. Dave leads efforts across research, discovery, translational medicine, regulatory strategy, and early development.
Prior to joining Code Bio, Dave served as Senior Vice President, Research at SwanBio Therapeutics directing translation of genetic therapies in development for the treatment of rare neurological diseases of the spinal cord. Prior to his role at SwanBio, Dave directed all preclinical research for the treatment of neurological diseases at Spark Therapeutics, Inc., where he oversaw development and growth of the central nervous system portfolio and team during his tenure.
Beyond his experience with SwanBio and Spark, Dave also co-founded two early-stage biotechnology companies, and previously served as faculty at Thomas Jefferson University. His expertise includes all aspects of experimental design and management with significant experience in molecular discovery and translation of basic research into preclinical animal models to support drug development.
Dave received a PhD in Molecular and Cell Biology from Thomas Jefferson University in 2005 and a B.Sc./Hons in Biomedical Sciences from Sheffield Hallam University in 1996.